This content is promotional in nature and is intended for consumer education about a commercially available product. It’s a paid advertorial: a commission is earned if you use the links in this article. Product claims come from the brand, not from this publication. MEDVi QUAD is a compounded prescription product, available only after a licensed provider evaluates you, and approval isn’t guaranteed. It’s not FDA-approved; compounded medications aren’t reviewed by the FDA for safety, effectiveness, or quality before reaching patients. Details here reflect brand materials and a direct brand communication reviewed in July 2026. Confirm anything that matters to you before enrolling.
MEDVi QUAD Reviews 2026: Is This New PT-141 Formula the ED Treatment Upgrade Men Have Been Waiting For? (Consumer Research)
MEDVi has revised the QUAD formula. According to a direct communication from MEDVi to this publication, PT-141 and L-Citrulline have taken the place of Vardenafil and Apomorphine. The current formula, verified on MEDVi’s live product page as of July 2026, now consists of sildenafil, tadalafil, PT-141, and L-Citrulline. Some earlier coverage of MEDVi QUAD, including previous articles on this platform, still describes the older formula and hasn’t been revised to reflect this change. This piece walks through what’s different, why it matters, and what’s worth checking before you enroll.
Maybe you saw an ad for MEDVi QUAD, or maybe you already knew the brand and came back because the ingredient list didn’t line up with what you remembered. Either way, your instincts were right. MEDVi has just updated its formula, and if you’re reading this now, you’re learning about it before nearly everyone else. Here’s exactly what’s changed, straight from MEDVi to this publication and verified on the brand’s own page.
QUAD is delivered through three separate entities, and that arrangement hasn’t shifted with the formula update:
- Platform: MEDVi, LLC (131 Continental Dr, Ste 305, Newark, DE 19713), which does not prescribe and is not a pharmacy
- Licensed medical group: CareGLP Affiliated P.C.s and OpenLoop Health, which make all prescribing decisions independently
- Compounding pharmacy: Belmar Pharma Solutions, which compounds and dispenses the prescription
Prescription medication becomes available only after a consultation and approval from a licensed healthcare provider, assuming it’s clinically appropriate. Approval is never guaranteed.
>>Start the MEDVi QUAD provider consultation process
MEDVi QUAD Quick Facts: What Changed
- Brand: MEDVi
- Program: QUAD
- What changed: Vardenafil and apomorphine were replaced with PT-141 and L-Citrulline
- Unchanged ingredients: Sildenafil, tadalafil
- Source of update: A direct communication from MEDVi to this publication, verified on MEDVi’s live product page
- As of: July 2026
- Current promotional price: $114 per month (as stated by the brand)
- Program type: Telehealth compounded prescription, not available over the counter
MEDVi QUAD Ingredients 2026: PT-141 and L-Citrulline Take the Place of Vardenafil and Apomorphine
Quick answer: MEDVi QUAD’s current formula, confirmed in July 2026, contains sildenafil, tadalafil, PT-141, and L-Citrulline. This takes over from the earlier formula of sildenafil, tadalafil, vardenafil, and apomorphine. MEDVi shared this change directly with this publication, and the update also appears on the brand’s live product page.
Per what MEDVi communicated to this publication, the QUAD formula has been revised. Vardenafil and Apomorphine are no longer part of it. PT-141 and L-Citrulline have taken their place. Sildenafil and Tadalafil remain the same as before. MEDVi’s live product page, checked in July 2026, currently displays the updated four-ingredient formula, matching that communication.
- Previous formula (being retired): Apomorphine, Vardenafil, Sildenafil, Tadalafil
- Current formula (as of July 2026): PT-141, L-Citrulline, Sildenafil, Tadalafil
Two of the four ingredients changed while two carried over. If you’re comparing this article to earlier MEDVi QUAD coverage, including previous pieces published on this platform, that’s the reason for the mismatch. That older coverage was correct for the formula in effect when it was published; it hasn’t been retroactively revised, and readers should treat the ingredient list here as the one currently in use.
Buyer takeaway: If you’ve read anything about MEDVi QUAD before today, cross-check the ingredient list against this one before enrolling. Two of the four active ingredients are different now.
>>Check the NEW QUAD ingredient list on MEDVi’s official page
Why the Change Matters and Isn’t Just a Label Swap
This isn’t a cosmetic update to the packaging. The two ingredients that were dropped and the two that replaced them function in different ways, and it’s worth understanding both sides rather than assuming the change is simply additive.
Apomorphine, the ingredient being removed, is FDA-approved for treating Parkinson’s disease and was included in the earlier QUAD ED formula for an off-label purpose. Vardenafil, also removed, belongs to the same drug class as sildenafil and tadalafil, a PDE5 inhibitor, which meant the previous formula combined three PDE5 inhibitors plus apomorphine in a single dose.
PT-141 (bremelanotide), the new addition, holds FDA approval as a standalone product for a different condition in a different group of patients, and its inclusion here is off-label. L-Citrulline, the other new ingredient, is an amino acid found naturally in the body. Research on it as a standalone ingredient centers mainly on nitric oxide production tied to exercise and cardiovascular outcomes rather than on ED specifically.
The net result: the updated formula still pairs two PDE5 inhibitors, sildenafil and tadalafil, with PT-141. That’s a genuine shift in what’s in the product, but it doesn’t change the central issue that matters most to a prescriber’s review, which is that combining sildenafil and tadalafil isn’t the typical way ED medications are prescribed, and using them together isn’t standard first-line practice. That was true of the old formula, and it’s still true of the current one. It’s a question to raise with your prescriber, not something this article, or MEDVi’s marketing, can settle on its own. How any individual responds to these ingredients, whether alone or combined, differs from person to person, and this article can’t predict that for you.
Buyer takeaway: Dropping apomorphine and vardenafil in favor of PT-141 (bremelanotide) and L-Citrulline is a genuine formula change, not just relabeling, but it doesn’t eliminate the two-PDE5-inhibitor combination that matters most when a prescriber reviews your case.
What to Ask Your Prescriber Before Starting
Because the current formula still pairs two PDE5 inhibitors, this is a topic for your prescriber to weigh in on, not something to judge from an advertisement or an ingredient-comparison article. As a class, PDE5 inhibitors carry cardiovascular considerations, including interactions with nitrate medications, and combining two of them isn’t standard first-line practice for treating ED.
Share every medication and supplement you take with your prescriber, along with any history of low blood pressure, heart conditions, or nitrate use, and ask directly why this particular combination, whether the old formula or the new one, is being recommended for you instead of a single-agent option. A licensed provider reviewing your individual health history is the one who should make that determination, not brand copy describing the update.
Buyer takeaway: Bring your complete medication and health history to the consultation no matter which formula version you originally read about. The prescriber’s review carries more weight than the ingredient label, and individual results and tolerability differ from patient to patient.
Current QUAD Pricing
Based on MEDVi’s live product page as reviewed in July 2026, promotional pricing begins at $114 per month, with $179 per month listed as a reference price, and free rush shipping included. Earlier coverage of the previous formula listed a $119 promotional starting price, a modest change worth noting alongside the ingredient update, since both figures come from the same source (MEDVi’s live page) at different points in time.
According to the brand, this price is stated to cover the physician consultation, the medication, and shipping. Pricing can change, so confirm the current figures on the official site before enrolling.
Buyer takeaway: The promotional price shifted along with the ingredients. Confirm today’s exact number at checkout rather than relying on any previously published figure, including the $119 amount from earlier coverage.
>>View current MEDVi QUAD pricing and what’s included
Cancellation and Refund Terms
According to MEDVi’s published Subscription Services Cancellation and Refund Policy, which is linked from MEDVi’s own site and separate from the ingredient update, cancellation requests need to arrive at least 72 hours before the next billing date to stop the upcoming charge. Miss that window and the next billing cycle will process before your cancellation takes effect.
Outside of cancellation due to medical disqualification by the provider, no refund is issued upon cancellation, and federal law generally bars returning prescription medications once they’ve been dispensed. These terms haven’t changed with the formula update and apply to enrollment under the current formula the same way they did under the previous one.
Buyer takeaway: Set a reminder to cancel at least 72 hours ahead of your billing date. That rule doesn’t reset or shift with the new ingredient list.
A Note on Earlier Coverage and This Update
MEDVi’s communication about this formula change went out to all approved partners, and it applies across every existing piece of QUAD coverage, not just one placement. Earlier coverage of MEDVi QUAD, including previous placements describing the three-entity telehealth structure, the 72-hour cancellation rule, the FDA regulatory context surrounding MEDVi’s broader business, and the platform’s enrollment process, remains correct on those points, none of which the formula change affects.
Where that earlier coverage lists apomorphine and vardenafil as active ingredients, it was reflecting the formula that was in place when each piece was published. Those articles were accurate at the time and haven’t been retroactively edited. This article’s ingredient list, PT-141, L-Citrulline, sildenafil, and tadalafil, is the current one as of July 2026, confirmed directly by MEDVi and cross-checked against the brand’s live page.
Readers looking for the fuller verification framework, including the three-entity structure in more detail, the complete cancellation and refund breakdown, a branded-medication comparison, and a full legitimacy checklist, can review earlier verification coverage of MEDVi QUAD’s original formula, cancellation terms, and regulatory context, published before this update. That coverage’s ingredient list is now superseded by this article; its other verification points are unaffected by the formula change.
Regulatory Context: What the FDA Warning Letter Does and Doesn’t Cover
Quick answer: Is MEDVi QUAD’s new formula FDA-approved? No. Neither the current formula (PT-141, L-Citrulline, sildenafil, tadalafil) nor the earlier one is FDA-approved as a compounded combination. A separate FDA warning letter sent to MEDVi in February 2026 concerned GLP-1 products only, not QUAD.
MEDVi, LLC received an FDA warning letter (#721455) dated February 20, 2026, addressing website claims about compounded semaglutide and tirzepatide, which are MEDVi’s GLP-1 weight-loss products. The letter made no mention of QUAD, and QUAD involves an entirely separate set of ingredients within a different health category altogether. An FDA warning letter isn’t a product ban, a court ruling, or a determination that a specific product is unsafe. It’s a formal notice that gives a company the chance to respond to and correct the issues identified.
Readers who want the complete regulatory picture, including the warning letter itself, related media coverage of MEDVi’s broader business, and pending litigation involving a clinical infrastructure partner, can review a dedicated regulatory breakdown covering the FDA warning letter and why it has no bearing on QUAD. MEDVi’s support channels can confirm current status directly.
Buyer takeaway: The FDA warning letter is genuine but unconnected to QUAD or to this formula update. Don’t let it substitute for verifying the ingredient-specific facts that actually apply here.
>>Learn more about MEDVi QUAD’s current program status
Things to Verify Before You Enroll
- Verify 1: Current formula at checkout. Confirm the ingredient list displayed at your specific checkout matches PT-141, L-Citrulline, sildenafil, and tadalafil, since brand pages and pricing can differ by promotion.
- Verify 2: Your eligibility. Approval hinges on your consultation with the licensed medical group; enrolling doesn’t guarantee it.
- Verify 3: Current pricing. Promotional pricing is subject to change, so confirm the current rate on the official site.
- Verify 4: Cancellation timing. The 72-hour pre-billing notice requirement applies no matter which formula version you’re on.
- Verify 5: Insurance. Any insurance coverage depends on your specific plan and isn’t confirmed by this article.
>>Confirm your eligibility with MEDVi’s intake process
Fast Facts
- Brand: MEDVi
- Program: QUAD by MEDVi
- Formula update source: Direct MEDVi communication to this publication, confirmed on MEDVi’s live page, July 2026
- Current ingredients: Sildenafil, Tadalafil, PT-141, L-Citrulline
- Previous ingredients (superseded): Sildenafil, Tadalafil, Vardenafil, Apomorphine
- Platform entity: MEDVi, LLC, Newark, DE
- Licensed medical group: CareGLP Affiliated P.C.s / OpenLoop Health
- Compounding pharmacy: Belmar Pharma Solutions
- Current promotional price: $114 per month (brand-stated, July 2026)
- Standard price: $179 per month (brand-stated reference price)
- Cancellation notice: 72 hours before the billing date
- Refund: Medical disqualification only; no other refunds per policy
Frequently Asked Questions
What exactly changed in the MEDVi QUAD formula?
Based on MEDVi’s communication to this publication, Vardenafil and Apomorphine have been removed and replaced with PT-141 and L-Citrulline. Sildenafil and Tadalafil are unchanged. The current formula is sildenafil, tadalafil, PT-141, and L-Citrulline.
Why does older MEDVi QUAD coverage list different ingredients?
Earlier coverage, including previous placements on this platform, was accurate for the formula in place at the time it was published. It hasn’t been retroactively updated. This article reflects the current formula as of July 2026.
Is the updated formula safer than the previous one?
That’s a clinical judgment for a prescriber to make, not a comparison this article draws. The updated formula still combines two PDE5 inhibitors (sildenafil and tadalafil), which carries the same class-level considerations it did before. Discuss your complete medical history with your prescriber regardless of which formula version comes up.
Did the price change along with the formula?
Yes, slightly. Earlier coverage listed a $119 promotional starting price; MEDVi’s current page shows $114. Both numbers come from MEDVi’s live product page at different points in time. Confirm the current price directly before enrolling.
Does the formula update affect the cancellation or refund policy?
No. MEDVi’s Subscription Services Cancellation and Refund Policy, including the 72-hour notice requirement and the medical-disqualification-only refund rule, is separate from the ingredient formula and applies the same way under the current formula as it did previously.
Is MEDVi QUAD FDA-approved?
No. Compounded medications, including QUAD in either formula version, are not FDA-approved and are not reviewed by the FDA for safety, effectiveness, or quality before reaching the market.
What is PT-141?
PT-141 is a commonly used name for bremelanotide, a compound that acts on melanocortin receptor pathways within the central nervous system. It carries FDA approval as a standalone product for a different indication in a different patient population, and its use in MEDVi QUAD’s compounded formula is off-label. This publication doesn’t independently verify how PT-141 performs within the specific compounded combination MEDVi dispenses.
What is bremelanotide?
Bremelanotide is the generic name for PT-141. The two terms describe the same compound. MEDVi’s marketing materials and product page use “PT-141,” while bremelanotide is the term found in its FDA-approved standalone product’s labeling and in clinical literature.
What is L-Citrulline used for?
L-Citrulline is an amino acid the body produces naturally, and ingredient-level research on it focuses mainly on its role as a nitric oxide precursor tied to exercise performance and cardiovascular outcomes rather than ED specifically. Its role within MEDVi QUAD’s compounded formula is described by the brand; this publication hasn’t independently evaluated its contribution to the finished combination.
Is L-Citrulline a prescription ingredient?
L-Citrulline on its own is an amino acid available outside prescription channels, but within MEDVi QUAD it’s compounded into a prescription formulation alongside sildenafil, tadalafil, and PT-141, and it’s dispensed only through the prescription pathway described in this article, not sold or evaluated here as a standalone supplement.
Does MEDVi QUAD still contain apomorphine?
No. Based on MEDVi’s communication to this publication and the brand’s current live page, apomorphine has been removed from the QUAD formula and replaced with PT-141 and L-Citrulline. Coverage describing apomorphine as a current ingredient is reflecting the previous formula version.
Is vardenafil still in MEDVi QUAD?
No. Vardenafil has been removed from the current formula. The updated version keeps sildenafil and tadalafil and adds PT-141 and L-Citrulline in place of vardenafil and apomorphine.
The Bottom Line
MEDVi has updated the QUAD formula. Vardenafil and Apomorphine are out, PT-141 and L-Citrulline are in, and sildenafil and tadalafil remain unchanged. This is confirmed directly by MEDVi and by the brand’s current live page. If you’ve come across QUAD described elsewhere with the older ingredient list, that isn’t a mistake; it’s simply outdated.
The program’s structure hasn’t shifted: three separate entities, physician-gated prescribing, and a 72-hour cancellation window. What’s actually different is what’s in the dose itself. If you’re weighing whether to try QUAD, the next step is the same one it’s always been: a consultation with MEDVi’s affiliated medical group, where a licensed provider decides whether the current formula makes sense for you. Visit the official MEDVi QUAD site for current program details before making your decision.
MEDVi Contact Information
- Company: MEDVi, LLC
- Address: 131 Continental Dr, Ste 305, Newark, DE 19713
- Email (QUAD product page): [email protected]
- Phone (QUAD product page): 24/7 patient support line
- Official site: Click Here
This content is promotional in nature and is intended for consumer education about a commercially available product. It’s a paid advertorial: a commission is earned if you use the links in this article. Product claims come from the brand, not from this publication. MEDVi QUAD is a compounded prescription product, available only after a licensed provider evaluates you, and approval isn’t guaranteed. It’s not FDA-approved; compounded medications aren’t reviewed by the FDA for safety, effectiveness, or quality before reaching patients. Details here reflect brand materials and a direct brand communication reviewed in July 2026. Confirm anything that matters to you before enrolling.
- About the Author
- Latest Posts
Our Editorial Team are writers and experts in their field. Their views and opinions may not always be the views of Wellbeing Magazine. If you are under the direction of medical supervision please speak to your doctor or therapist before following the advice and recommendations in these articles.
